Your browser doesn't support javascript.
loading
Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.
Feroldi, Emmanuel; Boaz, Mark; Yoksan, Sutee; Chokephaibulkit, Kulkanya; Thisyakorn, Usa; Pancharoen, Chitsanu; Monfredo, Céline; Bouckenooghe, Alain.
Afiliação
  • Feroldi E; Clinical Development, Sanofi Pasteur, Marcy l'Etoile, France.
  • Boaz M; Global Clinical Immunology, Sanofi Pasteur, Swiftwater, Pennsylvania.
  • Yoksan S; Center for Vaccine Development, Institute of Molecular Biosciences, Mahidol University, Thailand and Translational Research Unit, Chulabhorn Research Institute.
  • Chokephaibulkit K; Division of Infectious Diseases, Siriraj Hospital, Bangkok.
  • Thisyakorn U; Department of Pediatrics, Chulalongkorn Hospital, Bangkok, Thailand.
  • Pancharoen C; Department of Pediatrics, Chulalongkorn Hospital, Bangkok, Thailand.
  • Monfredo C; Clinical Development, Sanofi Pasteur, Marcy l'Etoile, France.
  • Bouckenooghe A; Medical Affairs and Clinical R&D, Sanofi Pasteur, Singapore.
J Infect Dis ; 215(2): 221-227, 2017 Jan 15.
Article em En | MEDLINE | ID: mdl-27815383
ABSTRACT

BACKGROUND:

The live-attenuated Japanese encephalitis (JE) vaccine (JE-CV; IMOJEV) induces a protective response in children. A shift in circulating JE virus strains suggests that a genotype shift phenomenon may occur throughout Southeast Asia. We assessed the neutralization of wild-type (WT) JE virus isolates at distal time points after vaccination.

METHODS:

We analyzed serum samples from a subset of 47 children who had received a JE-CV booster after an inactivated JE vaccine primary immunization. We measured antibody titers (50% plaque reduction neutralization test) using a panel of WT JE strains at baseline, then after the booster at 28 days and 6 months in all subjects present at the time points and in a subset at year 5. Three additional recent isolates were tested at year 5.

RESULTS:

Of 47 subjects, 43 (91.5%) subjects had JE neutralizing antibody titers ≥10 (reciprocal serum dilution) against the homologous strain before JE-CV boost; all were seroprotected up to year 5 after the JE-CV boost. Baseline WT seroprotection ranged between 78.7% and 87.2%; all subjects were seroprotected against the 4 WT strains at 28 days and 6 months; year 5 seroprotection ranged between 95.7% and 97.9%. Similar rates of protection against 3 additional WT isolates were observed at year 5.

CONCLUSIONS:

The long-term immune responses induced after a JE-CV booster dose in toddlers were able to neutralize WT viruses from various genotypes circulating in Southeast Asia and India. CLINICAL TRIALS REGISTRATION NCT00621764.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reações Cruzadas / Vacinas contra Encefalite Japonesa / Vírus da Encefalite Japonesa (Espécie) / Anticorpos Neutralizantes / Anticorpos Antivirais Limite: Animals / Child, preschool / Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: J Infect Dis Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reações Cruzadas / Vacinas contra Encefalite Japonesa / Vírus da Encefalite Japonesa (Espécie) / Anticorpos Neutralizantes / Anticorpos Antivirais Limite: Animals / Child, preschool / Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: J Infect Dis Ano de publicação: 2017 Tipo de documento: Article